Technical Analysis for LVCLF - Living Cell Technologies Ltd

Grade Last Price % Change Price Change
F 0.0091 -4.21% -0.0004
LVCLF closed down 4.21 percent on Thursday, May 6, 2021, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical LVCLF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -4.21%
Wide Bands Range Expansion -4.21%
Gapped Down Weakness -4.21%
MACD Bullish Signal Line Cross Bullish -17.27%
Narrow Range Bar Range Contraction -17.27%
Older End-of-Day Signals for LVCLF ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Living Cell Technologies Ltd Description

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercializing regenerative treatments which restore function using naturally occurring cells. LCT's lead product NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration. The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson's disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson's disease. It has the potential to be used in a number of other central nervous system indications such as Huntington's, Alzheimer's and motor neurone diseases. LCT's proprietary encapsulation technology, IMMUPEL, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system. LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes. LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Life Sciences Diabetes Immune System Stem Cells Parkinson's Disease Stock Exchanges Cell Biology Cell Therapy Restore Nerve Transplantation Encapsulation Treatment Of Parkinson's Disease Huntington The Australian Alzheimer's Natal Lexus Serious Diseases Growth Factors New Zealand Encapsulation Technology Type 1 Diabetes Motor Neurone Diseases Repair Disease Treatment For Patients With Parkinson's Disease

Is LVCLF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.215
52 Week Low 0.0004
Average Volume 26,586
200-Day Moving Average 0.0164
50-Day Moving Average 0.0118
20-Day Moving Average 0.0110
10-Day Moving Average 0.0101
Average True Range 0.0017
ADX 8.08
+DI 33.0472
-DI 42.4893
Chandelier Exit (Long, 3 ATRs ) 0.0109
Chandelier Exit (Short, 3 ATRs ) 0.0141
Upper Bollinger Band 0.0143
Lower Bollinger Band 0.0077
Percent B (%b) 0.21
BandWidth 60.0000
MACD Line -0.0008
MACD Signal Line -0.0006
MACD Histogram -0.0001
Fundamentals Value
Market Cap 5.2 Million
Num Shares 571 Million
EPS 0.00
Price-to-Earnings (P/E) Ratio -9.10
Price-to-Sales 1962.51
Price-to-Book 2.16
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0091
Resistance 3 (R3) 0.0091 0.0091 0.0091
Resistance 2 (R2) 0.0091 0.0091 0.0091 0.0091
Resistance 1 (R1) 0.0091 0.0091 0.0091 0.0091 0.0091
Pivot Point 0.0091 0.0091 0.0091 0.0091 0.0091
Support 1 (S1) 0.0091 0.0091 0.0091 0.0091 0.0091
Support 2 (S2) 0.0091 0.0091 0.0091 0.0091
Support 3 (S3) 0.0091 0.0091 0.0091
Support 4 (S4) 0.0091